Insights On Drug Development

  1. Compaction Simulation For Tablet Technology Transfer And Scale-Up 7/15/2026

    Compaction simulation de-risked tech transfer for a 40 mg fexuprazan tablet by defining optimal roller compaction and lubrication parameters before scale-up. Access the full case study to see the data.

  2. Predicting Softgel Stability And Shelf Life Using Accelerated Modeling 7/15/2026

    Predict ibuprofen softgel shelf life in 21 days instead of years. ASAPprime modeling identified PEG-ester degradants as the limiting factor, estimating 5.5-year and 3.8-year shelf lives before long-term studies concluded.

  3. Predicting Drug-Loading Limits In Tablet Formulations 7/15/2026

    Learn how predictive percolation modeling identified critical drug-loading limits of ~20% for crystalline API and ~15% for SDD forms, cutting tablet formulation trial-and-error significantly.

  4. Modeling Polymer Interactions To Improve Amorphous Solid Dispersion Stability 7/15/2026

    Molecular dynamics modeling revealed how hydrogen bonding between PVP and Eudragit drives stable amorphous solid dispersion formation, cutting formulation screening time significantly.

  5. Improving Bioavailability Through Predictive Modeling Of Solubility Enhancement Strategies 7/15/2026

    In silico modeling cut through formulation guesswork for a compound with 0.015 mg/mL solubility, delivering an 8× Cmax and 5× AUC improvement and Phase I progression.

  6. Patented Process For Olopatadine HCl API Intermediates 7/15/2026

    See how this patented Wittig-based process for olopatadine HCl achieves Z/E isomer ratios up to 4:1, eliminating dangerous reagents like n-butyl lithium while cutting purification complexity.

  7. Optimizing Clinical Supply Management With A One-Team Approach 7/15/2026

    See how NewAmsterdam Pharma managed 11 global studies across 51 countries and 835 sites for 12,000+ patients without overwhelming their internal team.

  8. A Scientist's Perspective On Advancing AAV Producer Cell Lines 7/15/2026

    Ten years of AAV producer cell line development distilled into one scientist's account, including a pivotal 2018 platform pivot and the lessons that followed. Read to understand what scalable gene therapy manufacturing actually takes.

  9. Platform Strategy For Improving Manufacturability And Efficacy In Bispecific Antibodies 7/15/2026

    Novel bispecific antibody engineering overcomes assembly and manufacturability challenges, enabling scalable production while preserving therapeutic function, stability, purity, and product quality.

  10. Bridging Innovation And Clinical Reality In ADC And AOC Development 7/10/2026

    ADCs have 12+ FDA approvals; AOCs are earlier-stage but gaining momentum. Learn what CMC risks developers must address early to reach the clinic without costly detours.